186 related articles for article (PubMed ID: 31107171)
1. Base Editing: Efficient Installation of Point Mutations with Minimal Byproducts.
Newby GA
Stem Cells Dev; 2019 Jun; 28(11):712-713. PubMed ID: 31107171
[No Abstract] [Full Text] [Related]
2. Gene editing using CRISPR-Cas9 for the treatment of lung cancer.
Castillo A
Colomb Med (Cali); 2016 Dec; 47(4):178-180. PubMed ID: 28293040
[No Abstract] [Full Text] [Related]
3. [CRISPR-Cas system as molecular scissors for gene therapy].
Heinz GA; Mashreghi MF
Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
[TBL] [Abstract][Full Text] [Related]
4. Editor's comment on "CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein".
Hohmann S
Mol Genet Genomics; 2017 Jun; 292(3):535-536. PubMed ID: 28251316
[No Abstract] [Full Text] [Related]
5. Genome Editing and Hematologic Malignancy.
Emmer BT; Ginsburg D
Annu Rev Med; 2020 Jan; 71():71-83. PubMed ID: 31469969
[TBL] [Abstract][Full Text] [Related]
6. Hematotherapy.
Mussolino C
Stem Cells Dev; 2019 Jun; 28(11):714. PubMed ID: 31081744
[No Abstract] [Full Text] [Related]
7. Gene editing based hearing impairment research and therapeutics.
Kang W; Sun Z; Zhao X; Wang X; Tao Y; Wu H
Neurosci Lett; 2019 Sep; 709():134326. PubMed ID: 31195050
[TBL] [Abstract][Full Text] [Related]
8. Take Risks and Constantly Challenge the Status Quo.
Cong L
Stem Cells Dev; 2019 Jun; 28(11):709. PubMed ID: 31090491
[No Abstract] [Full Text] [Related]
9. CRISPR/Cas9 for the treatment of haematological diseases: a journey from bacteria to the bedside.
Humbert O; Samuelson C; Kiem HP
Br J Haematol; 2021 Jan; 192(1):33-49. PubMed ID: 32506752
[TBL] [Abstract][Full Text] [Related]
10. Point: Treating Human Genetic Disease One Base Pair at a Time: The Benefits of Gene Editing.
Katsanis N
Clin Chem; 2018 Mar; 64(3):486-488. PubMed ID: 29490998
[No Abstract] [Full Text] [Related]
11. Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy.
Wang L; Zheng W; Liu S; Li B; Jiang X
Chembiochem; 2019 Mar; 20(5):634-643. PubMed ID: 30393919
[TBL] [Abstract][Full Text] [Related]
12. Huntington disease: Selective deactivation of Huntington disease mutant allele by CRISPR-Cas9 gene editing.
Malkki H
Nat Rev Neurol; 2016 Nov; 12(11):614-615. PubMed ID: 27686048
[No Abstract] [Full Text] [Related]
13. Gene Therapy 2017: Progress and Future Directions.
Keeler AM; ElMallah MK; Flotte TR
Clin Transl Sci; 2017 Jul; 10(4):242-248. PubMed ID: 28383804
[No Abstract] [Full Text] [Related]
14. Development and application of CRISPR/Cas9 technologies in genomic editing.
Zhang C; Quan R; Wang J
Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
[TBL] [Abstract][Full Text] [Related]
15. One Prime for All Editing.
Yang L; Yang B; Chen J
Cell; 2019 Dec; 179(7):1448-1450. PubMed ID: 31835025
[TBL] [Abstract][Full Text] [Related]
16. A new era of gene editing for the treatment of human diseases.
Kc M; Steer CJ
Swiss Med Wkly; 2019 Jan; 149():w20021. PubMed ID: 30685869
[TBL] [Abstract][Full Text] [Related]
17. The Development and Application of a Base Editor in Biomedicine.
Wang F; Zeng Y; Wang Y; Niu Y
Biomed Res Int; 2020; 2020():2907623. PubMed ID: 32855962
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9 technology and its application in haematological disorders.
Zhang H; McCarty N
Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas13a system: a novel approach to precision oncology.
Zhang J; You Y
Cancer Biol Med; 2020 Feb; 17(1):6-8. PubMed ID: 32296572
[No Abstract] [Full Text] [Related]
20. CRISPR/Cas9 genome engineering in hematopoietic cells.
Sürün D; von Melchner H; Schnütgen F
Drug Discov Today Technol; 2018 Aug; 28():33-39. PubMed ID: 30205879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
